Effect of tirofiban on no-reflow phenomenon during primary percutaneous coronary intervention in patients with acute ST-segment elevated myocardial infarction

Objective To evaluate the effect of platelet GPⅡb/Ⅲa antagonist tirofiban on no-reflow phenomenon during primary percutaneous coronary intervention(PCI)in patient's with acute ST segment elevated myocardial infarction(STEMI).Methods96 STEMI patients who underwent primary PCI were enrolled and then were randomly divided into two groups:Tirofiban group and control group.TIMI flow grade,serum troponin T(CTnT)24 hours after PCI were calculated.And.The composite primary end point event and bleeding complication at 24 hours and 30 days were also recorded.ResultsAs compared with group control,TIMI 3 grade flow in tirofiban group was increased(94.2%vs 83.1%)and TIMI 0~2 grade flow was decreased(5.8%vs 15.9%)obviously(P0.05).Composite primary end point events in tirofiban group decreased as compared with group control but the bleeding complication at 24 hours and 30 days were not significantly different between two groups.ConclusionAdmission with tirfiban during primary PCI to treatment STEMI patients can prevent no-reflow phenomenon effectively.